InvestorsHub Logo

TPX

Followers 0
Posts 40567
Boards Moderated 4
Alias Born 10/24/2013

TPX

Re: mick post# 66150

Thursday, 03/23/2017 1:11:10 PM

Thursday, March 23, 2017 1:11:10 PM

Post# of 144812
PMCB: In the company’s upcoming trial, the comparator arm that PharmaCyte’s pancreatic cancer therapy will be compared to is the combination of the cancer drug 5-fluorouracil (FU) and the compound leucovorin (LV). The necessary and quick decision was made by Dr. Manuel Hidalgo, the Principal Investigator for the upcoming clinical, Dr. Daniel Von Hoff with Translational Drug Development (TD2), the CRO for PharmaCyte’s clinical trial, and Dr. Matthias Löhr, the Chairman of PharmaCyte’s Medical and Scientific Advisory Board.

https://globenewswire.com/news-release/2017/02/13/916491/0/en/PharmaCyte-Biotech-Moves-Closer-to-Filing-IND-with-Naming-of-Comparator-Arm-for-Upcoming-Clinical-Trial-and-Discusses-Pivotal-Trial-Opportunity.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News